Semaglutide vs. Tirzepatide: What Miami Patients Need to Know

If you've been paying attention to the weight loss conversation over the past two years, you've heard the names: Ozempic, Wegovy, Mounjaro, Zepbound. The active ingredients — semaglutide and tirzepatide — have changed what's possible in weight medicine. But the marketing noise often drowns out the medical detail. At Viva Medical Center in Doral, FL, our patients ask us constantly: which one should I be on? Here's the honest clinical breakdown.

What Are GLP-1 Agonists?

GLP-1 (glucagon-like peptide-1) is a hormone your gut naturally releases after eating. It tells your pancreas to produce insulin, signals your brain that you're full, and slows gastric emptying so food leaves your stomach more gradually. GLP-1 receptor agonists are injectable medications that mimic and amplify this signal — dramatically reducing appetite, food cravings, and overall calorie intake.

Both semaglutide and tirzepatide work on GLP-1 receptors. The key difference is what tirzepatide adds.

Semaglutide (Ozempic / Wegovy): The Proven First Wave

Semaglutide (brand names: Ozempic for diabetes, Wegovy for obesity) is a pure GLP-1 receptor agonist. The landmark STEP trials (2021, New England Journal of Medicine) showed:

• Average weight loss of 14.9% of body weight over 68 weeks at the 2.4 mg/week dose
• Significant reduction in blood pressure, cholesterol, and A1c
• The SELECT trial (2023) demonstrated a 20% reduction in major cardiovascular events in patients with overweight/obesity and established heart disease

Semaglutide is FDA-approved for both type 2 diabetes (Ozempic) and chronic weight management (Wegovy). It's injected once weekly and has a well-established safety profile after years of widespread use.

Tirzepatide (Mounjaro / Zepbound): The Dual-Action Upgrade

Tirzepatide is a "twincretin" — it activates both GLP-1 receptors AND GIP (glucose-dependent insulinotropic polypeptide) receptors. GIP is another gut hormone that works synergistically with GLP-1. This dual mechanism translates to more potent effects.

The SURMOUNT-1 trial (2022, NEJM) — the largest obesity pharmacotherapy trial at the time — showed:

• Average weight loss of 20.9% of body weight at the highest dose (15 mg/week) over 72 weeks
• 34% of participants lost more than 25% of their body weight
• Superior A1c reduction compared to semaglutide in head-to-head trials

A direct head-to-head trial (SURPASS-2, 2021) showed tirzepatide outperformed semaglutide 1 mg on A1c reduction and weight loss at every dose level. Tirzepatide is FDA-approved as Mounjaro (diabetes) and Zepbound (obesity).

Side Effects: What's Similar, What's Different

Both medications share a similar side effect profile, driven by the GLP-1 mechanism:

• Nausea (most common, especially early; usually resolves in 4–8 weeks)
• Vomiting, diarrhea, constipation — GI effects that improve with slow dose titration
• Reduced appetite — this is the intended effect, not a side effect per se
• Injection site reactions — mild and uncommon

The black box warning on both: risk of thyroid C-cell tumors in rodent studies (human relevance unclear; contraindicated in patients with personal/family history of medullary thyroid carcinoma or MEN2). Both are contraindicated in pregnancy.

Which Should You Choose?

The evidence suggests tirzepatide produces more weight loss on average. But "on average" doesn't mean "for you." Your doctor at Viva Medical Center will consider:

• Insurance coverage: Both medications can exceed $1,000/month without coverage. We'll help navigate prior authorizations and manufacturer assistance programs
• History of GI disease: Some patients tolerate one better than the other
• Your goals: Diabetes control vs. pure weight loss vs. cardiovascular risk reduction may point to different choices
• Medication history: If you tried semaglutide and didn't respond well, tirzepatide may be the answer

The best medication is the one you can access, tolerate, and stay on long-term. This is a conversation best had with a physician who knows you.

Start Your Weight Loss Journey in Doral

We serve patients in English and Spanish. At Viva Medical Center, our weight loss program combines GLP-1 medication (when appropriate) with nutrition counseling, lifestyle coaching, and monthly check-ins. Learn about our weight loss program or book a consultation today.